Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD22 + status confers therapeutic sensitivity to Inotuzumab ozogamicin in patients with Acute Lymphoblastic Leukemia.
Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
This statement is based on a regulatory approval from the Health Canada:
BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |